Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1984 1
1985 1
1986 4
1987 2
1988 1
1990 1
1991 4
1992 1
1993 4
1994 6
1995 5
1996 4
1997 4
1998 7
1999 7
2000 2
2001 8
2002 2
2003 2
2005 3
2006 4
2007 6
2008 3
2009 4
2010 1
2013 1
2015 5
2016 1
2019 1
2020 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK. Kim RD, et al. Among authors: kohl ne. Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1. Cancer Discov. 2019. PMID: 31575541 Free article. Clinical Trial.
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
Drilon A, Horan JC, Tangpeerachaikul A, Besse B, Ou SI, Gadgeel SM, Camidge DR, van der Wekken AJ, Nguyen-Phuong L, Acker A, Keddy C, Nicholson KS, Yoda S, Mente S, Sun Y, Soglia JR, Kohl NE, Porter JR, Shair MD, Zhu V, Davare MA, Hata AN, Pelish HE, Lin JJ. Drilon A, et al. Among authors: kohl ne. Cancer Discov. 2023 Mar 1;13(3):598-615. doi: 10.1158/2159-8290.CD-22-0968. Cancer Discov. 2023. PMID: 36511802 Free PMC article.
Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics.
Koblan KS, Kohl NE, Omer CA, Anthony NJ, Conner MW, deSolms SJ, Williams TM, Graham SL, Hartman GD, Oliff A, Gibbs JB. Koblan KS, et al. Among authors: kohl ne. Biochem Soc Trans. 1996 Aug;24(3):688-92. doi: 10.1042/bst0240688. Biochem Soc Trans. 1996. PMID: 8878827 Review. No abstract available.
Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth.
Omer CA, Anthony NJ, Buser-Doepner CA, Burkhardt AL, deSolms SJ, Dinsmore CJ, Gibbs JB, Hartman GD, Koblan KS, Lobell RB, Oliff A, Williams TM, Kohl NE. Omer CA, et al. Among authors: kohl ne. Biofactors. 1997;6(3):359-66. doi: 10.1002/biof.5520060306. Biofactors. 1997. PMID: 9288406 Review.
Farnesyltransferase inhibitors versus Ras inhibitors.
Gibbs JB, Graham SL, Hartman GD, Koblan KS, Kohl NE, Omer CA, Oliff A. Gibbs JB, et al. Among authors: kohl ne. Curr Opin Chem Biol. 1997 Aug;1(2):197-203. doi: 10.1016/s1367-5931(97)80010-5. Curr Opin Chem Biol. 1997. PMID: 9667853 Review.
Farnesyltransferase inhibitors and anti-Ras therapy.
Gibbs JB, Kohl NE, Koblan KS, Omer CA, Sepp-Lorenzino L, Rosen N, Anthony NJ, Conner MW, deSolms SJ, Williams TM, Graham SL, Hartman GD, Oliff A. Gibbs JB, et al. Among authors: kohl ne. Breast Cancer Res Treat. 1996;38(1):75-83. doi: 10.1007/BF01803786. Breast Cancer Res Treat. 1996. PMID: 8825125 Review.
98 results